Phase I Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-858 for Treatment of Glabellar Lines
This study demonstrated that OBI-858 is well tolerated and showed preliminary efficacy. Overall, the OBI-858 has a clinically favorable profile of safety and efficacy that warrants proceeding to the next studies.
Authors
- C N Ou
- Tim-Mo Chen
- Chih‐Hung Lee (ORCID: https://orcid.org/0000-0001-9804-3874)
Institutions
- Tri-Service General Hospital (TW)
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1007/s13555-024-01309-7
- Citations
- 1
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.37